Background: Seems to be required for the activation of 5-LO (5-lipoxygenase). Could play an essential role in the transfer of arachidonic acid to 5-LO. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. Genetic variations in FLAP may be a cause of susceptibility to ischemic stroke [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Immunogen: Synthetic peptide derived from human FLAP protein.
Purification Method: Antigen Immunoaffiinity Purification
Concentration: Lot specific, see vial
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
References: 1. Dixon, R.A.F., et al. 'Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.; Nature 343:282-284(1990).2. Helgadottir, A., et al. 'The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.; Nat. Genet. 36:233-239(2004).
UniProt: P20292
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
